In a recent interview, Ewa Gajewska, Head of Product Management for SYNTHIA™ at Merck KGaA, discussed the transformative impact of SYNTHIA™ Retrosynthesis Software on pharmaceutical development. This innovative tool utilizes AI to automate the retrosynthetic analysis process, enabling chemists to quickly generate and evaluate multiple synthetic pathways for drug candidates. By streamlining the transition from computational design to practical synthesis, SYNTHIA™ significantly reduces the time and costs associated with drug development.

Gajewska highlighted that SYNTHIA™ not only accelerates the identification of viable synthetic routes but also supports sustainability by promoting greener chemistry practices. The software evaluates the feasibility of synthetic pathways, helping researchers prioritize simpler and more cost-effective options, which is crucial for meeting regulatory standards and environmental goals.

The interview also touched on SYNTHIA™'s integration with AI systems, enhancing the efficiency of drug discovery and manufacturing processes. Gajewska emphasized the importance of this technology in addressing the challenges of scaling up production while maintaining quality and compliance. As AI continues to evolve within the pharmaceutical sector, SYNTHIA™ is positioned as a key player in driving innovation and efficiency from lab to market.

For more insights from Gajewska and to explore how SYNTHIA™ is shaping the future of drug development, visit the full interview on Pharmaceutical Processing World.

Read Interview